Taigexyn，non-fluorinated broad-spectrum antibiotic，effective against Gram –positive and Gram-negative bacteria including MRSA, QR-MRSA, VRE. Excellent safety profile compare to other marketed quinolones，less likely to lead to resistance development。 Available in both oral and intravenous formulations for easy transition from hospital to out-patient。
Furaprevir，potent NS3/4A protease inhibitor，anchor in HCV Cocktail Regiment。 Effective against all six genotypes of HCV. Can be used with standard of care (peg-interferon + ribavirin) or other direct acting antivirals (DAAs). The combination of TG-2349 (Furaprevir, NS3/4A protease inhibitor)＋HEC DAG-181 (Yimitasvir , NS5A inhibitor) has already completed Phase I in China and initiated Phase II trial in November 2017.